Table 5.
Physical and Vital Sign Results, Mean Change from Baseline at Final On-Therapy Evaluation, Safety Population
| Children | Adolescents | |||||
|---|---|---|---|---|---|---|
| Placebo (n = 36) | Desvenlafaxine low exposure (n = 37) | Desvenlafaxine high exposure (n = 36) | Placebo (n = 84) | Desvenlafaxine low exposure (n = 85) | Desvenlafaxine high exposure (n = 85) | |
| Systolic BP, supine (mm Hg) | 0.6 | 0.1 | 0.5 | 0.3 | −0.1 | −0.4 |
| Diastolic BP, supine (mm Hg) | −0.6 | −0.4 | 1.9 | 0.2 | 0.9 | 0.1 |
| Pulse, supine (beats/min) | 1.5 | 3.7 | −1.4 | 2.1 | 1.7 | 1.4 |
| Systolic BP, orthostatic (mm Hg) | 0.9 | 0.4 | −0.3 | −1.3 | −0.6 | −0.2 |
| Diastolic BP, orthostatic (mm Hg) | −0.1 | 2.3 | −0.3 | −0.1 | 0 | 0 |
| Pulse, orthostatic (beats/min) | 1.4 | 1.1 | 4.3 | −2.0 | 1.1 | 2.5 |
| Weight (kg) | 1.0 | 0.1 | 0.5 | 0.4 | −0.2 | 0.2 |
| BMI (kg/m2) | 0.3 | −0.1 | 0.1 | 0 | −0.2 | −0.1 |
| Height (cm) | 0.6 | 0.5 | 0.5 | 0.4 | 1.7 | 0.5 |
BMI, body mass index; BP, blood pressure.